Compare DKL & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKL | AAPG |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2012 | N/A |
| Metric | DKL | AAPG |
|---|---|---|
| Price | $51.94 | $22.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $45.00 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 60.7K | 1.7K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 8.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.84 | N/A |
| Revenue Next Year | $10.17 | $368.64 |
| P/E Ratio | $17.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.59 | $17.56 |
| 52 Week High | $55.89 | $48.45 |
| Indicator | DKL | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 38.04 |
| Support Level | $42.58 | N/A |
| Resistance Level | $55.89 | $26.01 |
| Average True Range (ATR) | 1.76 | 0.93 |
| MACD | -0.34 | -0.11 |
| Stochastic Oscillator | 43.17 | 26.00 |
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.